Tag:
peptide
Latest Headlines
Latest Headlines
Ironwood, Protagonist ink peptide discovery deal
Ironwood Pharmaceuticals ( $IRWD ), 2009 Fierce 15 company , and Protagonist Therapeutics will work together to discover novel peptides for potential development by Ironwood. Under the terms of the
Discovery platform yields peptide prediction hit
The technology behind Compugen's recent announcement of positive therapeutic effects of a novel peptide in an animal study of inflammatory bowel disease is the company's Disease-Associated
Merck inks diabetes deal with fledgling Marcadia
Fledgling developer Marcadia Biotech has lined itself up with the pharmaceutical giant Merck in a licensing deal on the Indianapolis-based developer's work in diabetes. Marcadia has been working with
ALSO NOTED: BMS falls prey to subprime crisis;AZ cuts 200 U.K. workers;much more...
What's a drugmaker doing, investing in securities at least partly backed by subprime mortgages? Ask Bristol-Myers Squibb, which took a $275 million write-down on so-called "auction rate securities"
Press Release: Generex Biotechnology to Initiate Phase II Clinical Trial in Breast Cancer Patients
Press Release: Generex Biotechnology to Initiate Phase II Clinical Trial in Breast Cancer Patients
Press Release: Molecular Insight Pharmaceuticals Acquires Onalta
Press Release: Molecular Insight Pharmaceuticals Acquires Onalta
ALSO NOTED: Voyager ends Phase III early; Allegra cleared for use in children; and much more...
> DURECT announced that Voyager Pharmaceutical had told the company that it was ending a Phase III trial of Memryte for Alzheimer's disease in order to get a possibly earlier look at efficacy data. Memryte uses DURECT's DURIN technology to provide sustained release of the peptide leuprolide acetate and is based on Voyager's patented method of treatment of Alzheimer's disease. Release
> Sanofi-aventis' allergy …
ALSO NOTED: Pepscan Systems raises $9M in second round; Opexa starts Phase II Tovaxin study; and much more...
> Netherlands-based Pepscan Systems, a peptide based immunotherapy company, announced today that it has raised $9 million in a second financing round by issuance of equity to a group of Dutch investors. Release
> Chutes & Ladders: Dr. Jim A. Wright will step down as the President and CEO of Lorus Therapeutics on September 21st. …
Biogen inks $37.5M licensing deal with MondoBiotech
Biogen Idec is paying $7.5 million up front and up to $30 million in milestones for the right to develop a new therapy for pulmonary arterial hyperntension from MondoBiotech. Biogen is looking to gain marketing rights for Aviptadil in the U.S. and Europe. Biogen also agreed to make an equity investment of $5 million in MondoBiotech. Aviptadil is a synthetically produced human peptide that met its primary endpoint in a Phase II trial.
- read the AP report on the deal
Nastech to push ahead with obesity spray trial
Nastech Pharmaceutical has requested FDA approval to begin human trials of PYY3-36 spray to treat obesity. The spray delivers a hormone--the YY peptide--that researchers say plays a role in regulating the body's eating habits. Nastech shares were hammered earlier this year when Merck announced that a preliminary study of the hormone demonstrated no effect and was pulling out of a collaboration to develop the therapy. Nastech, however, says the study shows that the hormone is safe and …
